» Articles » PMID: 12842343

Characterisation of Drug Release from Cubosomes Using the Pressure Ultrafiltration Method

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2003 Jul 5
PMID 12842343
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Cubosomes have been proposed as a controlled release, intravenous drug delivery system. The objective of this study was to characterise cubosomes as either a therapeutically useful, controlled release delivery system, or as a burst release carrier such as submicron emulsions. The pressure ultrafiltration method and equilibrium dialysis were used to elucidate the in vitro drug release mechanisms. On dilution of cubosomes, lipophilic compounds were released rapidly when studied by the pressure ultrafiltration method. This agrees with the behaviour predicted from simple diffusion from the bulk non-dispersed cubic phase. In contrast, equilibrium dialysis incorrectly indicated sustained drug release from cubosomes. This study illustrates that cubosomes should be classified as a burst release delivery system where drug is released by diffusion from the cubic phase matrix, and that pressure ultrafiltration may have benefits over dialysis methods for measurement of drug release from colloidal particle-based drug delivery systems.

Citing Articles

Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications.

Attri N, Das S, Banerjee J, Shamsuddin S, Dash S, Pramanik A ACS Appl Bio Mater. 2024; 7(5):2677-2694.

PMID: 38613498 PMC: 11110070. DOI: 10.1021/acsabm.4c00153.


Cubic nanoparticles as potential carriers for a natural anticancer drug: development, in vitro and in vivo characterization.

Abdou R, Mojally M, Attia H, Dawoud M Drug Deliv Transl Res. 2023; 13(10):2463-2474.

PMID: 37010791 DOI: 10.1007/s13346-023-01325-8.


Novel pH-Responsive Cubosome and Hexosome Lipid Nanocarriers of SN-38 Are Prospective for Cancer Therapy.

Rajesh S, Zhai J, Drummond C, Tran N Pharmaceutics. 2022; 14(10).

PMID: 36297610 PMC: 9609773. DOI: 10.3390/pharmaceutics14102175.


Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation.

Sultan A, El Nashar N, Ashmawy S, El Maghraby G Int J Nanomedicine. 2022; 17:3543-3560.

PMID: 35983479 PMC: 9379123. DOI: 10.2147/IJN.S370235.


Mesoporous silica nanocarriers as drug delivery systems for anti-tubercular agents: a review.

Tella J, Adekoya J, Ajanaku K R Soc Open Sci. 2022; 9(6):220013.

PMID: 35706676 PMC: 9174711. DOI: 10.1098/rsos.220013.